DENTSPLY SIRONA Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item
NOTE 13 -ACCRUED LIABILITIES
Accrued liabilities were as follows:
| Year Ended December 31, | ||
|---|---|---|
| (in millions) | 2024 | 2023 |
| Payroll, commissions, bonuses, other cash compensation and employee benefits | $125 | $161 |
| Sales and marketing programs | 86 | 68 |
| Reserve for distributor rebates | 116 | 151 |
| Restructuring costs | 31 | 37 |
| Accrued vacation and holidays | 30 | 32 |
| Professional and legal costs | 105 | 25 |
| Current portion of derivatives | 12 | 18 |
| General insurance | 11 | 11 |
| Warranty liabilities | 21 | 24 |
| Third-party royalties | 5 | 5 |
| Deferred income | 95 | 91 |
| Accrued interest | 8 | 9 |
| Accrued property taxes | 5 | 6 |
| Current operating lease liabilities | 46 | 56 |
| Other | 58 | 55 |
| Accrued liabilities | $754 | $749 |
NOTE 14 -FINANCING ARRANGEMENTS
Short-Term Debt
Short-term debt was as follows:
| Year Ended December 31, | ||||||
|---|---|---|---|---|---|---|
| 2024 · 2023 | ||||||
| Principal · Interest · Principal · Interest | ||||||
| (in millions except percentages) · Balance · Rate · Balance · Rate | ||||||
| Corporate commercial paper facility | $410 | 5.3% | $225 | 5.8% | ||
| Other short-term borrowings | 11 | 4.9% | 20 | 4.9% | ||
| Add: Current portion of long-term debt | 128 | 77 | ||||
| Total short-term debt | $549 | $322 | ||||
| Maximum month-end short-term debt outstanding during the year | $549 | $399 | ||||
| Average amount of short-term debt outstanding during the year | 344 | 284 | ||||
| Weighted-average interest rate on short-term debt at year-end | 5.3% | 5.7% | ||||
Short-Term Borrowings
The Company has afive-year senior unsecured multi-currency revolving facility, for an aggregate principal amount of $700 million, that expires on May 12, 2028. The Company also has a $700 million commercial paper program. The $700 million multi-currency revolving credit facility serves as a back-up to the commercial paper facility, resulting in an aggregate of $700 million total available credit under the commercial paper facility and the multi-currency revolving credit facility. The Company had outstanding borrowings of $410 million and $225 million under the commercial paper facility at December 31, 2024 and December 31, 2023, respectively, andno outstanding borrowings under the multi-currency revolving credit facility. The Company also has access to $34 million in uncommitted short-term financing available under lines of credit from various financial institutions, which is reduced by outstanding short-term borrowings of $11 million. At December 31, 2024, the weighted-average interest rate for short-term debt was 5.3%.
At December 31, 2024, the Company had $313 million borrowings available under unused lines of credit, including lines available under its short-term arrangements and revolving credit facility.
Long-Term Debt
Long-term debt was as follows:
| Year Ended December 31, | ||||
|---|---|---|---|---|
| 2024 | 2023 | |||
| Principal | Interest | Principal | Interest | |
| (in millions except percentages) | Balance | Rate | Balance | Rate |
| Private placement notes 70 million euros due October 2024 | $— | —% | $77 | 1.0% |
| Private placement notes 25 million Swiss franc due December 2025 | 28 | 0.9% | 30 | 0.9% |
| Private placement notes 97 million euros due December 2025 | 100 | 2.1% | 107 | 2.1% |
| Private placement notes 26 million euros due February 2026 | 27 | 2.1% | 29 | 2.1% |
| Private placement notes 58 million Swiss franc due August 2026 | 64 | 1.0% | 69 | 1.0% |
| Private placement notes 106 million euros due August 2026 | 110 | 2.3% | 117 | 2.3% |
| Private placement notes 70 million euros due October 2027 | 72 | 1.3% | 77 | 1.3% |
| Private placement notes 8 million Swiss franc due December 2027 | 8 | 1.0% | 9 | 1.0% |
| Private placement notes 15 million euros due December 2027 | 16 | 2.2% | 17 | 2.2% |
| Private placement notes 140 million Swiss franc due August 2028 | 154 | 1.2% | 166 | 1.2% |
| Private placement notes 70 million euros due October 2029 | 72 | 1.5% | 77 | 1.5% |
| Fixed rate senior notes 750 million due June 2030 | 750 | 3.3% | 750 | 3.3% |
| Private placement notes 70 million euros due October 2030 | 72 | 1.6% | 77 | 1.6% |
| Private placement notes 45 million euros due February 2031 | 47 | 2.5% | 50 | 2.5% |
| Private placement notes 65 million Swiss franc due August 2031 | 72 | 1.3% | 77 | 1.3% |
| Private placement notes 12.6 billion Japanese yen due September 2031 | 80 | 1.0% | 89 | 1.0% |
| Private placement notes 70 million euros due October 2031 | 72 | 1.7% | 77 | 1.7% |
| Other borrowings, various currencies and rates | 4 | 14 | ||
| Hedge accounting fair value adjustment(a) | (28) | (28) | ||
| $1,720 | $1,881 | |||
| Less: Current portion | ||||
| (included in “Notes payable and current portion of long-term debt” in the Consolidated Balance Sheets) | 128 | 77 | ||
| Less: Long-term portion of deferred financing costs | 6 | 8 | ||
| Long-term portion | $1,586 | $1,796 | ||
(a) Represents the fair value of interest rate swap agreements entered into on a portion of the outstanding senior notes.
The Company’s revolving credit facility, term loans, and senior notes contain certain affirmative and negative debt covenants relating to the Company’s operations and financial condition. At December 31, 2024, the Company was in compliance with all debt covenants.
The contractual maturity dates of the Company’s long-term borrowings as of December 31, 2024 were as follows:
| (in millions) | |
|---|---|
| 2025 | $128 |
| 2026 | 204 |
| 2027 | 96 |
| 2028 | 154 |
| 2029 | 73 |
| 2030 and beyond | 1,093 |
| $1,748 | |
Interest expense, net includes interest income of $20 million, $16 million and $11 million for the years ended December 31, 2024, 2023 and 2022, respectively. Interest income primarily relates to interest-bearing cash equivalents and customer financing for the Company’s direct-to-consumer aligner solutions.
NOTE 15 -EQUITY
On November 7, 2023, the Board of Directors approved an increase to the authorized share repurchase program of $1.0 billion. Share repurchases may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions or other transactions in such amounts and at such times as the Company considers appropriate based upon prevailing market and business conditions and other factors. At December 31, 2024, the Company had authorization to repurchase $1.2 billion in shares of common stock remaining under the share repurchase program.
On March 3, 2023, the Company entered into an Accelerated Share Repurchase Agreement (“ASR Agreement”) with a financial institution to repurchase the Company’s common stock. The Company repurchased shares under the ASR Agreement as part of the share repurchase program described above. In 2023, the Company repurchased approximately 3.1 million shares, which were delivered during March 2023, at a volume-weighted average price of $38.74, representing $120 million of the total anticipated repurchase size. In April 2023, an additional 0.8 million shares were delivered upon the final settlement of the ASR Agreement, resulting in a total of 3.9 million shares repurchased under the agreement.
| (in millions, except per share amounts) · Initial Delivery · Final Settlement | |||||||
|---|---|---|---|---|---|---|---|
| Agreement Date | Amount Paid | Shares Received | Price per share | Value of Shares as a % of Contract Value | Settlement Date | Total Shares Received | Average Price per Share |
| March 3, 2023 | $150 | 3.1 | $38.74 | 80% | April 28, 2023 | 3.9 | $38.55 |
The ASR Agreement was accounted for as an initial delivery of common shares in a treasury stock transaction on March 6, 2023 of $121 million and a forward contract indexed to the Company’s common stock for an amount of common shares that was determined on the final settlement date. The forward contract met all applicable criteria for equity classification and was not accounted for as a derivative instrument for the quarter ended March 31, 2023. Therefore, the value of the forward contract of $30 million was recorded in Capital in excess of par value at March 31, 2023. Upon final settlement in April 2023, this amount was subsequently recorded as Treasury Stock in the Consolidated Balance Sheets. The initial delivery and final settlement of common stock reduced the weighted average common shares outstanding for both basic and diluted earnings per share. The forward contract did not impact the weighted average common shares outstanding for diluted earnings per share.
For the years ended December 31, 2024, 2023 and 2022, the Company repurchased outstanding shares of common stock at a cost of $250 million, $300 million and $150 million, respectively. For the year ended December 31, 2024, the treasury stock transactions resulted in an excise tax charge of $2 million for public company stock repurchases established by the Inflation Reduction Act of 2022.
For the years ended December 31, 2024 and 2023, stock options exercised and the proceeds received at exercise werenot significant. For the year ended December 31, 2022, the Company received proceeds of $6 million primarily as a result of stock options exercised in the amount of 0.1 million. It is the Company’s practice to issue shares from treasury stock when stock options are exercised and RSUs vest.
Total outstanding shares of common stock and treasury stock were as follows:
| (in millions) | Shares of Common Stock | Shares of Treasury Stock | OutstandingShares |
|---|---|---|---|
| Balance at December 31, 2021 | 264.5 | (47.1) | 217.4 |
| Shares of treasury stock issued | — | 0.9 | 0.9 |
| Repurchase of common stock at an average cost of $48.22 | — | (3.1) | (3.1) |
| Balance at December 31, 2022 | 264.5 | (49.3) | 215.2 |
| Shares of treasury stock issued | — | 0.8 | 0.8 |
| Repurchase of common stock at an average cost of $34.20 | — | (8.8) | (8.8) |
| Balance at December 31, 2023 | 264.5 | (57.3) | 207.2 |
| Shares of treasury stock issued | — | 1.0 | 1.0 |
| Repurchase of common stock at an average cost of $26.65 | — | (9.4) | (9.4) |
| Balance at December 31, 2024 | 264.5 | (65.7) | 198.8 |
NOTE 16 -INCOME TAXES
The components of loss before income taxes were as follows:
| Year Ended December 31, | |||
|---|---|---|---|
| (in millions) | 2024 | 2023 | 2022 |
| United States | $(307) | $(6) | $(531) |
| Foreign | (629) | (169) | (524) |
| Total loss before income taxes | $(936) | $(175) | $(1,055) |
The components of the benefit for income taxes from operations were as follows:
| Year Ended December 31, | |||
|---|---|---|---|
| (in millions) | 2024 | 2023 | 2022 |
| Current: | |||
| U.S. federal | $(6) | $1 | $1 |
| U.S. state | 1 | — | 4 |
| Foreign | 115 | 86 | 118 |
| Total | $110 | $87 | $123 |
| Deferred: | |||
| U.S. federal | $(61) | $4 | $(145) |
| U.S. state | (1) | (3) | (17) |
| Foreign | (74) | (131) | (66) |
| Total | $(136) | $(130) | $(228) |
| Total benefit for income taxes | $(26) | $(43) | $(105) |
The reconciliation of the U.S. federal statutory tax rate to the effective rate were as follows:
| Year Ended December 31, | ||||||
|---|---|---|---|---|---|---|
| (in millions, except percentages) · 2024 · 2023 · 2022 | ||||||
| Statutory U.S. federal income tax rate | $(197) | 21.0% | $(37) | 21.0% | $(222) | 21.0% |
| Effect of: | ||||||
| State income taxes, net of federal benefit | — | — | (2) | 1.4 | (11) | 1.0 |
| Federal benefit of R&D and foreign tax credits | (7) | 0.8 | (17) | 10.0 | (8) | 0.8 |
| U.S. other permanent differences | 3 | (0.3) | 5 | (2.7) | 9 | (0.9) |
| Tax effect of international operations | 42 | (4.5) | (65) | 37.2 | (5) | 0.5 |
| Global Intangible Low Taxed Income (GILTI) | 9 | (1.0) | 12 | (7.0) | 20 | (1.9) |
| Foreign Derived Intangible Income (FDII) | — | — | (9) | 5.2 | (8) | 0.8 |
| Net effect of tax audit activity | 23 | (2.5) | (6) | 3.2 | 15 | (1.4) |
| Tax effect of enacted statutory rate changes on Non-U.S. jurisdictions | 3 | (0.3) | 1 | (0.4) | (3) | 0.3 |
| Federal tax on unremitted earnings of certain foreign subsidiaries | (1) | 0.1 | 2 | (0.9) | 1 | (0.1) |
| Valuation allowance adjustments | (13) | 1.3 | 5 | (3.2) | (9) | 0.8 |
| Tax effect of impairment of goodwill and intangibles | 106 | (11.3) | 60 | (34.6) | 114 | (10.8) |
| Other | 6 | (0.5) | 8 | (4.4) | 2 | (0.2) |
| Effective income tax rate on operations | $(26) | 2.8% | $(43) | 24.8% | $(105) | 9.9% |
The tax effect of significant temporary differences giving rise to deferred tax assets and liabilities were as follows:
| Year Ended December 31, | ||
|---|---|---|
| (in millions) | 2024 | 2023 |
| Deferred tax assets | ||
| Employee benefit accruals | $40 | $55 |
| Inventory | 19 | 15 |
| Miscellaneous accruals | 50 | 51 |
| Other | 44 | 44 |
| Lease right-of-use liability | 39 | 46 |
| Net unrealized gains/losses included in AOCI | — | 36 |
| Foreign tax credit and R&D carryforward | 41 | 43 |
| Tax loss carryforwards and other tax attributes | 1,554 | 948 |
| Total deferred tax assets | $1,787 | $1,238 |
| Less: Valuation allowances | (1,503) | (863) |
| Total deferred tax assets, net | $284 | $375 |
| Deferred tax liabilities | ||
| Identifiable intangible assets | $(110) | $(298) |
| Property, plant and equipment | (28) | (38) |
| Lease right-of-use asset | (38) | (46) |
| Net unrealized gains/losses included in AOCI | (9) | — |
| Taxes on unremitted earnings of foreign subsidiaries | (6) | (8) |
| Total deferred tax liabilities | (191) | (390) |
| Net deferred tax assets (liabilities) | $93 | $(15) |
Deferred tax assets and liabilities included in the following Consolidated Balance Sheets line items at December 31 were as follows:
| Year Ended December 31, | ||
|---|---|---|
| (in millions) | 2024 | 2023 |
| Assets | ||
| Other noncurrent assets | $222 | $213 |
| Liabilities | ||
| Deferred income taxes | $129 | $228 |
The Company has $36 million of foreign tax credit carryforwards at December 31, 2024, of which $30 million will expire in 2025 and $6 million will expire at various times from 2028 through 2031.
The Company has tax loss carryforwards related to certain foreign and domestic subsidiaries of approximately $7,482 million at December 31, 2024, of which $7,214 million expires at various times through 2044 and $268 million may be carried forward indefinitely. These are reflected as deferred income tax assets at December 31, 2024, and are comprised of future tax benefits of $1,458 million and $96 million, before valuation allowances, related to tax loss carryforwards and disallowed interest carryforwards, respectively. As of December 31, 2023 the Company’s deferred tax assets included$873 million of tax loss carryforwards and $74 million of disallowed interest carryforwards. The increase in tax loss carryforwards in 2024 is primarily the result of impairment losses.
At December 31, 2024, the Company has recorded $1,395 million of valuation allowance to offset the future tax benefit of net operating losses, $29 million to offset the future tax benefit of foreign tax credits, and $79 million of valuation allowance for other deferred tax assets. The Company has recorded these valuation allowances due to the uncertainty that these assets can be realized in the future. The increase in the valuation allowance is attributable to the increase in the tax loss carryforwards generated in 2024 as there is uncertainty that these assets can be realized in the future.
The Company has recorded $6 million of withholding taxes on certain undistributed earnings of its foreign subsidiaries that the Company anticipates will be repatriated. Undistributed earnings of foreign subsidiaries and related companies that are considered to be permanently invested amounted to $348 million at December 31, 2024.
Tax Contingencies
The total amount of gross unrecognized tax benefits at December 31, 2024 is approximately $137 million, including interest, of which approximately $51 million represents the amount of unrecognized tax benefits that, if recognized, would affect the effective income tax rate. It is reasonably possible that certain amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date of the Company’s consolidated financial statements. Expiration of statutes of limitations in various jurisdictions during the next twelve months could include unrecognized tax benefits of approximately $6 million, which, if recognized, would affect the effective income tax rate.
The total amount of accrued interest and penalties were $9 million and $4 million at December 31, 2024 and 2023, respectively. The Company has consistently classified interest and penalties recognized in its consolidated financial statements as income taxes based on the accounting policy election of the Company. The Company recognized a tax expense of $5 million for the year ended December 31, 2024, and a tax benefit of $2 million in 2023 related to interest and penalties.
The increase in unrecognized tax benefits in 2024 is primarily related to transfer pricing adjustments in certain jurisdictions, offset by a decrease from foreign currency translation.
The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. The significant jurisdictions include the United States and Germany. The Company has concluded all U.S. federal income tax matters for years through 2014 with the Internal Revenue Service (“IRS”). The Company is currently under IRS audit for the tax years 2015 and 2016. The Company is under audit in Germany for the tax years 2014 through 2021. For additional information on the IRS and German audits, see Note 21, Commitments and Contingencies.
The activity recorded for unrecognized tax benefits were as follows:
| Year Ended December 31, | |||
|---|---|---|---|
| (in millions) | 2024 | 2023 | 2022 |
| Unrecognized tax benefits at beginning of period | $132 | $49 | $34 |
| Gross change for prior-period positions | 18 | 1 | 12 |
| Gross change for current year positions | 1 | 95 | 4 |
| Decrease due to settlements and payments | (13) | (9) | — |
| Decrease due to statute expirations | — | (4) | — |
| Increase due to effect of foreign currency translation | — | — | — |
| Decrease due to effect from foreign currency translation and other | (10) | — | (1) |
| Unrecognized tax benefits at end of period | $128 | $132 | $49 |
NOTE 17 -BENEFIT PLANS
Defined Contribution Plans
The Company maintains both U.S. and non-U.S. employee defined contribution plans. The primary U.S. plan, the Dentsply Sirona Inc. 401(k) Savings Plan (the “Plan”), allows eligible employees to contribute a portion of their cash compensation to the Plan on a tax-deferred basis, and the Company provides a matching contribution. The Plan includes various investment funds. Each eligible participant who elects to contribute to the Plan will receive a matching contribution of 100% on the first 1% contributed and 50% on the next 5% contributed for a total maximum matching contribution of 3.5%. At its discretion, the Company may make additional non-elective cash contributions based on a percentage of compensation to participant accounts. The Company did not make any additional non-elective cash contributions in connection with 2024 compensation. In addition to the Plan, the Company also maintains various other U.S. and non-U.S. defined contribution and non-qualified deferred compensation plans. The annual expenses, net of forfeitures, of these plans were $34 million, $43 million and $41 million for the years ended December 31, 2024, 2023, and 2022, respectively.
Defined Benefit Plans
The Company maintains defined benefit pension plans for certain employees in Austria, France, Germany, Indonesia, Italy, Japan, the Netherlands, Norway, Sweden, Switzerland, Taiwan, and the United States. These plans provide benefits based upon age, years of service and remuneration. Substantially all the German and Swedish plans are unfunded book reserve plans. Most employees and retirees outside the United States are covered by government health plans.
The Company predominantly derives its discount rates by applying the specific spot rates along the yield curve to the relevant projected cash flows; or, in markets where there is an absence of a sufficiently deep corporate bond market, it uses liability durations in establishing its discount rates, which are observed from indices of high-grade corporate or government bond yield in the respective economic regions of a given plan. For the large defined benefits pension plans, the Company uses a spot rate approach for the estimation of the Service cost and Interest cost components of benefit cost by applying the specific spot rates along the yield curve to the relevant projected cash flows.
Significant changes in the retirement plan benefit obligations for the year ended December 31, 2024 include a $9 million actuarial gain primarily attributable to the increase in discount rates, the effect of which is slightly offset by a $1 million loss due to a change in the lump sum withdrawal rate for the Swiss plan. The changes also include a $4 million actuarial loss due to plan experience being different than anticipated.
Significant changes in the retirement plan benefit obligations for the year ended December 31, 2023 include a $35 million actuarial loss primarily attributable to the decrease in discount rates, the effect of which is slightly offset by the change in inflation and salary increase assumptions in some plans. The changes also include a $3 million actuarial loss due to plan experience being different than anticipated.
Defined Benefit Pension Plan Assets
The primary investment strategy is to ensure that the assets of the plans, along with anticipated future contributions, will be invested in order that the benefit entitlements of employees, pensioners and beneficiaries covered under the plan can be met when due with high probability. Pension plan assets consist mainly of common stock and fixed income investments. The target allocations for defined benefit plan assets are 30% to 65% equity securities,30% to 65% fixed income securities,0% to 15% real estate, and 0% to 25% in all other types of investments. Equity securities include investments in companies located both in and outside the United States. Equity securities in the defined benefit pension plans do not include Company common stock contributed directly by the Company. Fixed income securities include corporate bonds of companies from diversified industries, government bonds, mortgage notes and pledge letters. Other types of investments include investments in mutual funds, insurance contracts, hedge funds and real estate. These plan assets are not recorded in the Company’s Consolidated Balance Sheet as they are held in trust or other off-balance sheet investment vehicles.
The defined benefit pension plan assets maintained in Austria, Germany, Norway, the Netherlands, Switzerland and Taiwan all have separate investment policies but generally have an objective to achieve a long-term rate of return in excess of 2% while at the same time mitigating the impact of investment risk associated with investment categories that are expected to yield greater than average returns. In accordance with the investment policies, the plans’ assets were invested in the following investment categories: interest-bearing cash, U.S. and foreign equities, foreign fixed income securities (primarily corporate and government bonds), insurance company contracts, real estate and hedge funds.
Reconciliation of changes in the defined benefit obligations, fair value of assets and statement of funded status were as follows:
| Year Ended December 31, | ||
|---|---|---|
| (in millions) | 2024 | 2023 |
| Change in Benefit Obligation | ||
| Benefit obligation at beginning of year | $511 | $440 |
| Service cost | 11 | 10 |
| Interest cost | 12 | 14 |
| Participant contributions | 5 | 4 |
| Actuarial (gains) losses | (4) | 38 |
| Effect of exchange rate changes | (36) | 26 |
| Benefits paid | (21) | (21) |
| Benefit obligation at end of year | $478 | $511 |
| Change in Plan Assets | ||
| Fair value of plan assets at beginning of year | $207 | $182 |
| Actual return on assets | 16 | 10 |
| Effect of exchange rate changes | (15) | 17 |
| Employer contributions | 16 | 15 |
| Participant contributions | 5 | 4 |
| Benefits paid | (21) | (21) |
| Fair value of plan assets at end of year | $208 | $207 |
| Funded status at end of year | $(270) | $(304) |
The amounts recognized in the accompanying Consolidated Balance Sheets, net of tax effects, were as follows:
| Location In The · Year Ended December 31, | |||
|---|---|---|---|
| (in millions) | Consolidated Balance Sheets | 2024 | 2023 |
| Other noncurrent assets | Other noncurrent assets | $4 | $5 |
| Deferred tax asset | Other noncurrent assets | 8 | 11 |
| Total assets | $12 | $16 | |
| Current liabilities | Accrued liabilities | $(10) | $(11) |
| Other noncurrent liabilities | Other noncurrent liabilities | (264) | (298) |
| Deferred tax liability | Deferred income taxes | (4) | (2) |
| Total liabilities | $(278) | $(311) | |
| Accumulated other comprehensive income | Accumulated other comprehensive loss | 23 | 36 |
| Net amount recognized | $(243) | $(259) | |
Amounts recognized in AOCI were as follows:
| Year Ended December 31, | ||
|---|---|---|
| (in millions) | 2024 | 2023 |
| Net actuarial loss | $30 | $48 |
| Net prior service cost | (3) | (3) |
| Before tax AOCI | $27 | $45 |
| Less: Deferred taxes | 4 | 9 |
| Net of tax AOCI | $23 | $36 |
Information for pension plans with a projected or accumulated benefit obligation in excess of plan assets was as follows:
| Year Ended December 31, | ||
|---|---|---|
| (in millions) | 2024 | 2023 |
| Projected benefit obligation | $274 | $323 |
| Accumulated benefit obligation | 263 | 310 |
| Fair value of plan assets | — | 15 |
Components of net periodic benefit cost were as follows:
| Year Ended December 31, · Location in the Consolidated Statements of Operations | ||||
|---|---|---|---|---|
| (in millions) · 2024 · 2023 · 2022 | ||||
| Service cost | $4 | $4 | $5 | Cost of products sold |
| Service cost | 7 | 6 | 7 | Selling, general and administrative expenses |
| Interest cost | 12 | 14 | 5 | Other (income) expense, net |
| Expected return on plan assets | (5) | (6) | (4) | Other (income) expense, net |
| Amortization of prior service credit | (1) | (1) | (1) | Other (income) expense, net |
| Amortization of net actuarial loss | 2 | — | 8 | Other (income) expense, net |
| Curtailment and settlement gains | — | — | (1) | Other (income) expense, net |
| Net periodic benefit cost | $19 | $17 | $19 | |
Other changes in plan assets and benefit obligations recognized in AOCI were as follows:
| Year Ended December 31, | |||
|---|---|---|---|
| (in millions) | 2024 | 2023 | 2022 |
| Net actuarial (gains) losses | $(17) | $37 | $(125) |
| Amortization | (1) | 1 | (7) |
| Total recognized in AOCI | $(18) | $38 | $(132) |
| Total recognized in net periodic benefit cost and AOCI | $1 | $55 | $(113) |
Assumptions
The weighted average assumptions used to determine benefit obligations for the Company’s plans, principally in foreign locations were as follows:
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Interest crediting rate | 2.0% | 2.3% | 2.5% |
| Discount rate | 2.5% | 2.6% | 3.2% |
| Rate of compensation increase | 2.4% | 2.5% | 2.6% |
The weighted average assumptions used to determine net periodic benefit cost for the Company’s plans, principally in foreign locations were as follows:
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Interest crediting rate | 2.3% | 2.5% | 1.3% |
| Discount rate | 2.6% | 3.2% | 1.1% |
| Expected return on plan assets | 2.9% | 3.2% | 2.2% |
| Rate of compensation increase | 2.5% | 2.6% | 2.6% |
| Measurement date | 12/31/2024 | 12/31/2023 | 12/31/2022 |
To develop the assumptions for the expected long-term rate of return on assets, the Company considered the current level of expected returns on risk free investments (primarily U.S. government bonds), the historical level of the risk premium associated with the other asset classes in which the assets are invested and the expectations for future returns of each asset class. The expected return for each asset class was then weighted based on the target asset allocations to develop the assumptions for the expected long-term rate of return on assets.
Fair Value Measurements of Plan Assets
The fair values of the Company’s pension plan assets at December 31, 2024 and 2023 are presented in the table below by asset category. Approximately 83% of the total plan assets are categorized as Level 1, as the values assigned to these pension assets are based on quoted prices available in active markets. For the other category levels, a description of the valuation is provided in Note 1, Significant Accounting Policies, under the “Fair Value Measurement” heading.
| (in millions) | Total | Level 1 | Level 2 | Level 3 |
|---|---|---|---|---|
| Assets Category | ||||
| Cash and cash equivalents | $6 | $6 | $— | $— |
| Equity securities: | ||||
| International | 67 | 67 | — | — |
| Fixed income securities: | ||||
| Fixed rate bonds (a) | 79 | 79 | — | — |
| Other types of investments: | ||||
| Mutual funds (b) | 21 | 21 | — | — |
| Insurance contracts | 24 | — | — | 24 |
| Hedge funds | 10 | — | — | 10 |
| Real estate | 1 | — | — | 1 |
| Total | $208 | $173 | $— | $35 |
| (in millions) | Total | Level 1 | Level 2 | Level 3 |
|---|---|---|---|---|
| Assets Category | ||||
| Cash and cash equivalents | $7 | $7 | $— | $— |
| Equity securities: | ||||
| International | 63 | 63 | — | — |
| Fixed income securities: | ||||
| Fixed rate bonds (a) | 84 | 84 | — | — |
| Other types of investments: | ||||
| Mutual funds (b) | 19 | 19 | — | — |
| Insurance contracts | 26 | — | — | 26 |
| Hedge funds | 7 | — | — | 7 |
| Real estate | 1 | — | — | 1 |
| Total | $207 | $173 | $— | $34 |
(a) This category includes fixed income securities invested primarily in Swiss bonds, foreign bonds denominated in Swiss francs, foreign currency bonds, mortgage notes and pledged letters.
(b) This category includes mutual funds balanced between moderate income generation and moderate capital appreciation with investment allocations of approximately 50% equities and 50% fixed income investments.
A reconciliation from December 31, 2022 to December 31, 2024 for the plan assets categorized as Level 3 was as follows:
| (in millions) | InsuranceContracts | HedgeFunds | RealEstate | Total |
|---|---|---|---|---|
| Balance at December 31, 2022 | $24 | $9 | $1 | $34 |
| Actual return on plan assets: | ||||
| Relating to assets still held at the reporting date | 2 | — | — | 2 |
| Purchases, sales and settlements, net | (1) | (3) | — | (4) |
| Effect of exchange rate changes | 1 | 1 | — | 2 |
| Balance at December 31, 2023 | $26 | $7 | $1 | $34 |
| Actual return on plan assets: | ||||
| Relating to assets still held at the reporting date | $1 | $1 | $— | $2 |
| Purchases, sales and settlements, net | (1) | 3 | — | 2 |
| Effect of exchange rate changes | (2) | (1) | — | (3) |
| Balance at December 31, 2024 | $24 | $10 | $1 | $35 |
Fair values for Level 3 assets are determined as follows:
Insurance Contracts: The value of the asset represents the mathematical reserve of the insurance policies and is calculated by the insurance firms using their own assumptions.
Hedge Funds: The investments are valued using the net asset value provided by the administrator of the fund, which is based on the fair value of the underlying securities.
Real Estate: Investment is stated by its appraised value.
Cash Flows
In 2025, the Company expects to make employer contributions of $17 million to its defined benefit pension plans.
Estimated Future Benefit Payments
Total benefits expected to be paid from the plans in the future are as follows:
| (in millions) | PensionBenefits |
|---|---|
| 2025 | $25 |
| 2026 | 25 |
| 2027 | 26 |
| 2028 | 23 |
| 2029 | 23 |
| 2030-2034 | 131 |
NOTE 18 -RESTRUCTURING AND OTHER COSTS
Restructuring and other costs for the years ended December 31, 2024, 2023 and 2022 were recorded in the Consolidated Statements of Operations as follows:
| Affected Line Item in the Consolidated Statements of Operations | Year Ended December 31, | ||
|---|---|---|---|
| (in millions) | 2024 | 2023 | 2022 |
| Cost of products sold | $10 | $4 | $— |
| Selling, general, and administrative expenses | 32 | 3 | — |
| Restructuring costs | 53 | 67 | 14 |
| Total Restructuring and other costs | $95 | $74 | $14 |
Restructuring and other costs of $95 million were recorded in the year ended December 31, 2024, which consisted primarily of employee severance benefits and other costs related to the restructuring plans approved by the Board of Directors of the Company on July 29, 2024 (the “2024 Plan”) and on February 14, 2023 (the “2023 Plan”), as well as certain asset impairments resulting from the strategic actions related to the Byte aligners business beginning in October 2024 (the “Byte Realignment”).
Restructuring Plans
With the 2024 Plan, the Company seeks to improve operational performance and drive stockholder value creation. In connection with the 2024 Plan, which is expected to be substantially completed by the end of 2025, the Company anticipates a net reduction in the Company’s global workforce of approximately 2% to 4%. The proposed changes are subject to co-determination processes with employee representative groups in countries where required. Actions taken under the 2024 Plan seek to further streamline the Company’s operations and global footprint, as well as improve alignment of the Company’s cost structure with its strategic growth objectives. As of December 31, 2024, the Company has incurred $28 million in restructuring charges under the 2024 Plan since its inception. In total, the Company expects to incur between $35 million and $50 million in non-recurring restructuring charges under the 2024 Plan, primarily related to employee transition, severance payments, and employee benefits, which are expected to be expensed and paid in cash by the end of 2025.
With the 2023 Plan, the Company sought to restructure the business through a new operating model with five global business units, optimize central functions and overall management infrastructure, and implement other efforts aimed at cost savings. The 2023 Plan’s annual cost savings target of $200 million has been substantially met, with the benefits mostly offset in the short term by additional investments in sales personnel, the Company’s new global Enterprise Resource Planning (“ERP”) system, and other transformation initiatives. As of December 31, 2024, the Company has incurred $87 million in restructuring charges under the 2023 Plan since its inception, primarily related to employee transition, severance payments, employee benefits, and facility closure costs, and $20 million in other non-recurring costs related to restructuring activities, which mostly consist of consulting, legal, and other professional service fees. Remaining restructuring charges attributable to the 2023 Plan are not expected to be material.
The estimates of the charges and expenditures that the Company expects to incur in connection with the 2024 Plan, and the timing thereof, are subject to several assumptions, including local law requirements in various jurisdictions and co-determination aspects in countries where required. Actual amounts may differ materially from estimates. In addition, the Company may incur additional charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the 2024 Plan.
The liabilities associated with the Company’s restructuring plans are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets. Activity in the Company’s restructuring accruals at December 31, 2024 was as follows:
| Severance | ||||
|---|---|---|---|---|
| (in millions) | 2022 and Prior Plans | 2023 Plans | 2024 Plans | Total |
| Balance at December 31, 2023 | $2 | $37 | $— | $39 |
| Provisions and adjustments | 1 | 23 | 30 | 54 |
| Amounts applied | (2) | (44) | (11) | (57) |
| Change in estimates | — | (4) | — | (4) |
| Balance at December 31, 2024 | $1 | $12 | $19 | $32 |
| Other Restructuring Costs | ||||
|---|---|---|---|---|
| (in millions) | 2022 and Prior Plans | 2023 Plans | 2024 Plans | Total |
| Balance at December 31, 2023 | $1 | $— | $— | $1 |
| Provisions and adjustments | — | 3 | — | 3 |
| Amounts applied | — | (3) | — | (3) |
| Balance at December 31, 2024 | $1 | $— | $— | $1 |
The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:
| (in millions) | December 31, 2023 | Provisions and Adjustments | AmountsApplied | Change in Estimates | December 31, 2024 |
|---|---|---|---|---|---|
| Connected Technology Solutions | $13 | $23 | $(25) | $(2) | $9 |
| Essential Dental Solutions | 17 | 15 | (20) | (1) | 11 |
| Orthodontic and Implant Solutions | 9 | 11 | (11) | — | 9 |
| Wellspect Healthcare | 1 | 5 | (2) | (1) | 3 |
| All Other | — | 3 | (2) | — | 1 |
| Total | $40 | $57 | $(60) | $(4) | $33 |
The Company’s restructuring accruals at December 31, 2023 were as follows:
| Severances | ||||
|---|---|---|---|---|
| (in millions) | 2021 and Prior Plans | 2022 Plans | 2023 Plans | Total |
| Balance at December 31, 2022 | $4 | $3 | $— | $7 |
| Provisions and adjustments | — | 2 | 62 | 64 |
| Amounts applied | (2) | (3) | (24) | (29) |
| Change in estimates | — | (2) | (1) | (3) |
| Balance at December 31, 2023 | $2 | $— | $37 | $39 |
| Other Restructuring Costs | ||||
|---|---|---|---|---|
| (in millions) | 2021 and Prior Plans | 2022 Plans | 2023 Plans | Total |
| Balance at December 31, 2022 | $— | $1 | $— | $1 |
| Provisions and adjustments | 1 | — | 9 | 10 |
| Amounts applied | (1) | — | (8) | (9) |
| Change in estimates | — | — | (1) | (1) |
| Balance at December 31, 2023 | $— | $1 | $— | $1 |
The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:
| (in millions) | December 31, 2022 | Provisions and Adjustments | AmountsApplied | Change in Estimates | December 31, 2023 |
|---|---|---|---|---|---|
| Connected Technology Solutions | $3 | $18 | $(8) | $— | $13 |
| Essential Dental Solutions | 4 | 25 | (10) | (2) | 17 |
| Orthodontic and Implant Solutions | 1 | 16 | (7) | (1) | 9 |
| Wellspect Healthcare | — | 5 | (3) | (1) | 1 |
| All Other | — | 10 | (10) | — | — |
| Total | $8 | $74 | $(38) | $(4) | $40 |
Byte Realignment
The changes to the Byte clear aligners business disclosed in Note 6, Segment and Geographic Information, have resulted in significant reductions in revenue forecasts and a triggering event in the fourth quarter of 2024 to evaluate the recoverability of assets attributable to Byte. The Company recorded long-term tangible asset charges, which include production equipment and capitalized software, as well as working capital for certain inventory and customer receivables specific to Byte. Additionally, the Company recorded a full impairment of the Byte trademark intangible asset.
In addition to these impairments, the Company recorded a full accrual for expected customer refunds and other reimbursement payments stemming from the cessation of sales, which resulted in a $35 million reduction to net sales, of which $13 million was paid during the three months ended December 31, 2024, with the remainder expected to be paid in 2025.
The impact of these charges related to the Byte Realignment was as follows:
| Location in the Consolidated Statements of Operations | |
|---|---|
| (in millions) | December 31, 2024 |
| Net sales | |
| Change in refund estimate | $(35) |
| Cost of products sold | |
| Inventory reserve | (8) |
| Selling, general, and administrative expenses | |
| Intangible asset impairment - trademark | (152) |
| Property, plant and equipment write-off | (17) |
| Accounts receivable reserve and prepaid write-off | (10) |
| Total impact on operating loss | $(222) |
NOTE 19 -FINANCIAL INSTRUMENTS AND DERIVATIVES
Derivative Instruments and Hedging Activities
The Company’s activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates and interest rates. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company’s operating results and cash flows. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert fixed rate debt into variable rate debt or vice versa. The Company does not hold derivative instruments for trading or speculative purposes.
The following summarizes the notional amounts of cash flow hedges, hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes by derivative instrument type at December 31, 2024 and the notional amounts expected to mature during the next 12 months.
| Aggregate Notional Amount | Aggregate Notional Amount Maturing within 12 Months | |
|---|---|---|
| (in millions) | ||
| Cash Flow Hedges | ||
| Foreign exchange forward contracts | $— | $— |
| Total derivative instruments designated as cash flow hedges | $— | $— |
| Hedges of Net Investments | ||
| Foreign exchange forward contracts | $827 | $83 |
| Cross currency basis swaps | 276 | — |
| Total derivative instruments designated as hedges of net investments | $1,103 | $83 |
| Fair Value Hedges | ||
| Foreign exchange forward contracts | $— | $— |
| Interest rate swaps | 150 | — |
| Total derivative instruments designated as fair value hedges | $150 | $— |
| Derivative Instruments not Designated as Hedges | ||
| Foreign exchange forward contracts | $602 | $602 |
| Total derivative instruments not designated as hedges | $602 | $602 |
Cash Flow Hedges
The Company hedges select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings or losses. The Company designates certain foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts through AOCI based on the assessed effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value is deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time-value component of the fair value of the derivative is reported on a straight-line basis in Cost of products sold in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.
These foreign exchange forward contracts generally have maturities up to 18 months, which is the period over which the Company is hedging exposures to variability of cash flows, and the counterparties to the transactions are typically large international financial institutions.
The Company enters into interest rate swap contracts to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.
On May 26, 2020, the Company paid $31 million to settle the $150 million notional Treasury rate lock contract, which partially hedged the interest rate risk of the $750 million Senior Notes due June 2030. This loss is amortized over theten-year life of the notes. As of December 31, 2024 and December 31, 2023, $16 million and $19 million, respectively, of this loss is remaining to be amortized from AOCI in future periods.
AOCI Release
Overall, the derivatives designated as cash flow hedges are considered to be highly effective for accounting purposes. At December 31, 2024, the Company expects to reclassify $3 million of deferred net losses on cash flow hedges recorded in AOCI in the Consolidated Statements of Operations during the next 12 months. For the rollforward of derivative instruments designated as cash flow hedges in AOCI, see Note 5, Comprehensive Loss.
Hedges of Net Investments in Foreign Operations
The Company has significant investments in foreign subsidiaries. The net assets of these subsidiaries are exposed to volatility in foreign currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of these exposures. The derivative instruments consist of foreign exchange forward contracts and cross-currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in the aforementioned instruments, which are designated as hedges of net investments, and the intrinsic value changes in these instruments are recorded on AOCI, net of tax effects. The time-value component of the fair value of the derivative instrument is amortized on a straight-line basis in Other (income) expense, net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows, except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows.
The fair value of the foreign currency exchange forward contracts and cross-currency basis swaps is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects.
On July 2, 2021, the Company entered into a cross-currency basis swap of a notional amount of $300 million, which matures on June 3, 2030. The cross-currency basis swap is designated as a hedge of net investments. This contract effectively converts a portion of the $750 million bond coupon from 3.3% to 1.7%, which will result in a net reduction of Other (income) expense, net.
On May 25, 2021, the Company re-established its euro net investment hedge portfolio by entering into eight foreign exchange forward contracts, each with a notional amount of 10 million euro. The original contracts have quarterly maturity dates through March 2023 and the Company entered into additional foreign exchange contracts as individual contracts within the portfolio matured. As of December 31, 2024, the euro net investment hedge portfolio has an aggregate notional value of 160 million euro with maturity dates through December 2025.
On July 20, 2023, the Company entered into a Swiss franc foreign exchange forward contract designated as a net investment hedge. The foreign exchange forward contract had a notional amount of 600 million Swiss francs. This net investment hedge was settled in September 2023 which resulted in cash receipts totaling $32 million. The Company subsequently entered into Swiss franc foreign exchange contracts designated as net investment hedges with a total notional amount of 600 million Swiss francs. This portfolio of contracts has semi-annual maturity dates through July 2028.
Fair Value Hedges
The Company has intercompany loans denominated in Swedish kronor that are exposed to volatility in foreign currency exchange rates. The Company employs derivative financial instruments to hedge these exposures. The Company accounts for these designated foreign exchange forward contracts as fair value hedges. The Company measures the effectiveness of fair value hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be recorded in Other (income) expense, net in the Consolidated Statements of Operations. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other (income) expense, net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.
On July 1, 2021, the Company entered into variable interest rate swaps with a notional amount of $250 million, which effectively converted a portion of the underlying fixed rate of 3.3% on the $750 million Senior Notes due June 2030 to a variable interest rate. Of the $250 million notional amount, $100 million has a term offive-years maturing on June 1, 2026 and $150 million has a term ofnine years maturing on March 1, 2030.
On February 13, 2024, the Company paid $9 million to settle the variable interest rate swap with a notional amount of $100 million which was originally set to mature on June 1, 2026. This closure of the interest rate swap will result in a loss of $8 million being amortized over the remaining life of the Senior Notes due June 2030.
Derivative Instruments Not Designated as Hedges
The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The Company primarily uses foreign exchange forward contracts to hedge these risks. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other (income) expense, net in the Consolidated Statements of Operations. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.
Gains and losses recorded in the Company’s Consolidated Statements of Operations related to the derivative instruments not designated as hedges for the years ended December 31, 2024 and 2023 were not significant.
Derivative Instrument Activity
The effect of derivative hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss were as follows:
| Year Ended December 31, 2024 | Year Ended December 31, 2023 | Year Ended December 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| (in millions) | Cost of products sold | Interest expense, net | Other (income) expense, net | Cost of products sold | Interest expense, net | Other (income) expense, net | Cost of products sold | Interest expense, net | Other (income) expense, net |
| Total amounts of line items presented in the Consolidated Statements of Operations in which the effects of cash flow, net investment or fair value hedges are recorded | $1,835 | $69 | $(12) | $1,879 | $81 | $9 | $1,795 | $65 | $53 |
| (Gain) loss on Cash Flow Hedges | |||||||||
| Foreign exchange forward contracts | $— | $— | $— | $1 | $— | $— | $(3) | $— | $— |
| Interest rate swaps | — | 3 | — | — | 3 | — | — | 3 | — |
| Gain on Hedges of Net Investment | |||||||||
| Cross currency basis swaps | $— | $— | $(5) | $— | $— | $(5) | $— | $— | $(5) |
| Foreign exchange forward contracts | — | — | (25) | — | — | (12) | — | — | (2) |
| (Gain) loss on Fair Value Hedges: | |||||||||
| Interest rate swaps | $— | $8 | $— | $— | $11 | $— | $— | $1 | $— |
| Foreign exchange forward contracts | — | — | — | — | — | — | — | — | (27) |
| (Gain) loss on Derivative Instruments not Designated as Hedges | |||||||||
| Foreign exchange forward contracts | $— | $— | $2 | $— | $— | $8 | $— | $— | $(4) |
| Amount of Gain or (Loss) Recognized in AOCI · Amount of Gain or (Loss) Reclassified from AOCI into Income | |||||||
|---|---|---|---|---|---|---|---|
| Year Ended December 31, · Consolidated Statements of Operations Location · Year Ended December 31, | |||||||
| (in millions) · 2024 · 2023 · 2022 · 2024 · 2023 · 2022 | |||||||
| Cash Flow Hedges | |||||||
| Foreign exchange forward contracts | $— | $— | $(1) | Cost of products sold | $— | $(1) | $3 |
| Interest rate swaps | — | — | — | Interest expense, net | (3) | (3) | (3) |
| Hedges of Net Investments | |||||||
| Cross currency basis swaps | $11 | $(18) | $30 | Other (income) expense, net | $— | $— | $— |
| Foreign exchange forward contracts | 37 | (29) | 11 | Other (income) expense, net | — | — | — |
| Fair Value Hedges | |||||||
| Interest rate swaps | $— | $— | $— | Other (income) expense, net | $— | $— | $— |
| Foreign exchange forward contracts | — | 2 | (2) | Interest expense, net | — | — | — |
Consolidated Balance Sheets Location of Derivative Fair Values
The fair value and the location of the Company’s derivatives in the Consolidated Balance Sheets were as follows:
| (in millions) | PrepaidExpensesand OtherCurrent Assets | OtherNoncurrentAssets | AccruedLiabilities | OtherNoncurrentLiabilities |
|---|---|---|---|---|
| Designated as Hedges: | ||||
| Foreign exchange forward contracts | $5 | $9 | $— | $1 |
| Interest rate swaps | — | — | 4 | 17 |
| Cross currency basis swaps | 4 | 14 | — | — |
| Total | $9 | $23 | $4 | $18 |
| Not Designated as Hedges: | ||||
| Foreign exchange forward contracts | $4 | $— | $8 | $— |
| Total | $4 | $— | $8 | $— |
| (in millions) | PrepaidExpensesand OtherCurrent Assets | OtherNoncurrentAssets | AccruedLiabilities | OtherNoncurrentLiabilities |
|---|---|---|---|---|
| Designated as Hedges: | ||||
| Foreign exchange forward contracts | $3 | $— | $4 | $47 |
| Interest rate swaps | — | — | 9 | 19 |
| Cross currency basis swaps | 4 | 4 | — | — |
| Total | $7 | $4 | $13 | $66 |
| Not Designated as Hedges: | ||||
| Foreign exchange forward contracts | $5 | $— | $5 | $— |
| Total | $5 | $— | $5 | $— |
Balance Sheet Offsetting
Substantially all of the Company’s derivative contracts are subject to netting arrangements, whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets.
Offsetting of financial assets and liabilities under netting arrangements at December 31, 2024 were as follows:
| Gross Amounts Not Offset in the Consolidated Balance Sheets | ||||||
|---|---|---|---|---|---|---|
| (in millions) | Gross Amounts Recognized | Gross Amounts Offset in the Consolidated Balance Sheets | Net Amounts Presented in the Consolidated Balance Sheets | Financial Instruments | Cash Collateral Received/Pledged | Net Amount |
| Assets | ||||||
| Foreign exchange forward contracts | $18 | $— | $18 | $(5) | $— | $13 |
| Cross currency basis swaps | 18 | — | 18 | (6) | — | 12 |
| Total assets | $36 | $— | $36 | $(11) | $— | $25 |
| Liabilities | ||||||
| Foreign exchange forward contracts | $9 | $— | $9 | $(4) | $— | $5 |
| Interest rate swaps | 21 | — | 21 | (7) | — | 14 |
| Total liabilities | $30 | $— | $30 | $(11) | $— | $19 |
Offsetting of financial assets and liabilities under netting arrangements at December 31, 2023 were as follows:
| Gross Amounts Not Offset in the Consolidated Balance Sheets | ||||||
|---|---|---|---|---|---|---|
| (in millions) | Gross Amounts Recognized | Gross Amounts Offset in the Consolidated Balance Sheets | Net Amounts Presented in the Consolidated Balance Sheets | Financial Instruments | Cash Collateral Received/Pledged | Net Amount |
| Assets | ||||||
| Foreign exchange forward contracts | $8 | $— | $8 | $(5) | $— | $3 |
| Cross currency basis swaps | 8 | — | 8 | (4) | — | 4 |
| Total assets | $16 | $— | $16 | $(9) | $— | $7 |
| Liabilities | ||||||
| Foreign exchange forward contracts | $56 | $— | $56 | $(7) | $— | $49 |
| Interest rate swaps | 28 | — | 28 | (2) | — | 26 |
| Total liabilities | $84 | $— | $84 | $(9) | $— | $75 |
NOTE 20 -FAIR VALUE MEASUREMENT
The estimated fair and carrying values of the Company’s total debt were $2,037 million and $2,135 million, respectively, at December 31, 2024. At December 31, 2023, the estimated fair and carrying values were $2,018 million and $2,118 million, respectively. The fair value of long-term debt is determined by discounting future cash flows using interest rates available at December 31, 2024 to companies with similar credit ratings for issuances with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes.
Assets and liabilities measured at fair value on a recurring basis
The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows:
| (in millions) | Total | Level 1 | Level 2 | Level 3 |
|---|---|---|---|---|
| Assets | ||||
| Cross currency interest rate swaps | $18 | $— | $18 | $— |
| Foreign exchange forward contracts | 18 | — | 18 | — |
| Total assets | $36 | $— | $36 | $— |
| Liabilities | ||||
| Interest rate swaps | $21 | $— | $21 | $— |
| Foreign exchange forward contracts | 9 | — | 9 | — |
| Contingent considerations on acquisitions | 4 | — | — | 4 |
| Total liabilities | $34 | $— | $30 | $4 |
| (in millions) | Total | Level 1 | Level 2 | Level 3 |
|---|---|---|---|---|
| Assets | ||||
| Cross currency interest rate swaps | $8 | $— | $8 | $— |
| Foreign exchange forward contracts | 8 | — | 8 | — |
| Total assets | $16 | $— | $16 | $— |
| Liabilities | ||||
| Interest rate swaps | $28 | $— | $28 | $— |
| Foreign exchange forward contracts | 56 | — | 56 | — |
| Contingent considerations on acquisitions | 4 | — | — | 4 |
| Total liabilities | $88 | $— | $84 | $4 |
Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, and credit risks.
There were no transfers between fair value measurement levels during the years ended December 31, 2024 and 2023.
Assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3)
The Company’s Level 3 liabilities at December 31, 2024 are related to earn-out obligations from acquisitions and licensing arrangements. The following table presents a reconciliation of the Company’s Level 3 holdings measured at fair value on a recurring basis using unobservable inputs:
| (in millions) | Level 3 |
|---|---|
| Balance, December 31, 2022 | $4 |
| Payments | — |
| Balance, December 31, 2023 | $4 |
| Payments | — |
| Balance, December 31, 2024 | $4 |
There were no additional purchases or transfers of Level 3 financial instruments in 2024 and 2023.
NOTE 21 -COMMITMENTS AND CONTINGENCIES
Contingencies
On December 19, 2018, a putative class action was filed in the U.S. District Court for the Eastern District of New York (the “EDNY Court”) against the Company and certain individual defendants. The case was narrowed following its inception. The plaintiff’s claims which, as discussed below, have now been settled in principal, are that the Company and certain individual defendants violated U.S. securities laws by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. (“Sirona”) with DENTSPLY International Inc. (the “Merger”) and that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products. In addition, the plaintiff alleges that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between May 6, 2016 and August 7, 2018. The plaintiff asserts claims on behalf of a putative class consisting of all purchasers of the Company's stock during the period from December 8, 2015 through August 6, 2018. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021, with briefing on the motion fully submitted on May 21, 2021. The Company’s motion to dismiss was denied in a ruling by the EDNY Court on March 29, 2023, and the Company’s answer to the second amended complaint was filed on May 12, 2023. Following additional motion practice—which remained outstanding with the EDNY Court—and discovery, the parties engaged in settlement discussions with the assistance of a mediator, and, in January 2025, reached a settlement in principal to resolve the case in full for $84 million, of which the Company expects to receive an offsetting insurance receivable of approximately $78 million while paying the rest in cash. A binding term sheet for the settlement has been signed, which is subject to negotiation and approval by the EDNY Court of a full settlement agreement. The excess of the settlement liability as of December 31, 2024 over the corresponding insurance policy receivable resulted in $6 million of legal expense which was recorded during the period.
On June 2, 2022, the Company was named as a defendant in a putative class action filed in the U.S. District Court for the Southern District of Ohio captioned City of Miami General Employees’ & Sanitation Employees’ Retirement Trust v. Casey, Jr. et al., No. 2:22-cv-02371, and on July 28, 2022, the Company was named as a defendant in a putative class action filed in the U.S. District Court for the Southern District of New York (the “SDNY Court”) captioned San Antonio Fire and Police Pension Fund v. Dentsply Sirona Inc. et al., No. 1:22-cv-06339 (together, the “Securities Litigation”). The complaints in the Securities Litigation are substantially similar and both allege that, during the period from June 9, 2021 through May 9, 2022, the Company, Mr. Donald M. Casey Jr., the Company’s former Chief Executive Officer, and Mr. Jorge Gomez, the Company’s former Chief Financial Officer, violated U.S. securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the manner in which the Company recognized revenue tied to distributor rebate and incentive programs. On March 27, 2023, the Court in the Southern District of Ohio ordered the transfer of the putative class action to the SDNY Court. On June 1, 2023, the SDNY Court consolidated the two separate actions under case No. 1:22-cv-06339 and appointed as lead plaintiffs for the putative class the City of Birmingham Retirement and Relief System, the El Paso Firemen & Policemen’s Pension Fund, and the Wayne County Employees’ Retirement System (collectively, the “Lead Plaintiffs”). Lead Plaintiffs filed an amended class action complaint on July 28, 2023 (the “Amended Complaint”). In addition to asserting the same claims against the Company, Mr. Casey, and Mr. Gomez, the Amended Complaint added the Company’s former Chief Accounting Officer, Mr. Ranjit S. Chadha, as a defendant (collectively, “Defendants”). On October 10, 2023, Defendants filed a motion to dismiss the Amended Complaint. Lead Plaintiffs’ opposition to Defendants’ motion to dismiss was filed on December 8, 2023, and Defendants’ reply was filed on January 8, 2024. The motion to dismiss was granted as to Mr. Chadha and granted in part and denied in part as to the Company, Mr. Casey, and Mr. Gomez in a ruling by the SDNY Court on May 1, 2024. The Company’s answer to the Amended Complaint was filed on May 21, 2024. On November 15, 2024, Lead Plaintiffs filed a motion to certify the matter as a class action, to appoint Lead Plaintiffs as class representatives, and to appoint Robbins Geller Rudman & Dowd LLP as class counsel. Defendants’ opposition to Lead Plaintiffs’ motion was filed on December 20, 2024, and Lead Plaintiffs’ reply is due on February 28, 2025.
In addition to the Securities Litigation, as previously disclosed, the Company voluntarily contacted the SEC following the Company’s announcement on May 10, 2022 of the internal investigation by the Audit and Finance Committee of the Company’s Board of Directors. The Company continues to cooperate with the SEC regarding this matter.
Separately, on July 13, 2023, Dentsply Sirona stockholder George Presura filed a stockholder derivative suit in the Delaware Court of Chancery captioned George Presura, Derivatively on Behalf of Nominal Defendant Dentsply Sirona Inc. v. Donald M. Casey Jr. et al. and Dentsply Sirona, Inc., No. 2023-0708-NAC (the “Presura Derivative Litigation”). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company’s Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The derivative complaint in this case contains allegations similar to those in the Securities Litigation, and it alleges that during the period from June 9, 2021 through July 13, 2023, various of the defendants breached fiduciary duties, committed corporate waste, and misappropriated information to conduct insider trading by making materially false and misleading statements or omissions regarding the Company’s recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels. On August 4, 2023, the Delaware Court of Chancery stayed the Presura Derivative Litigation until the earlier of public announcement of a settlement of the Securities Litigation or resolution of the pending motion to dismiss in the Securities Litigation.
Additionally, on March 26, 2024, Dentsply Sirona stockholder Calvin Snee filed a stockholder derivative suit in the Delaware Court of Chancery captioned Calvin Snee, derivatively on behalf of Dentsply Sirona Inc. v. Donald M. Casey Jr., et al. and Dentsply Sirona Inc, No. 2024-0308 (the “Snee Derivative Litigation”). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company’s Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The derivative complaint in this case contains allegations similar to those in the Presura Derivative Litigation and the Securities Litigation, and it alleges that beginning in 2021, various of the defendants breached fiduciary duties, misappropriated information to conduct insider trading, and were unjustly enriched by making materially false and misleading statements or omissions regarding the Company’s recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels.
On May 2, 2024, the Delaware Court of Chancery issued an order consolidating and staying the Presura Derivative Litigation and Snee Derivative Litigation.
On July 19, 2024, Dentsply Sirona stockholder Frank Manfre filed a stockholder derivative suit in the Delaware Court of Chancery captioned Frank Manfre, derivatively on behalf of nominal defendant Dentsply Sirona Inc. v. Donald M. Casey Jr. et al. and Dentsply Sirona Inc., No. 2024-0763 (the “Manfre Derivative Litigation”). The complaint asserts claims against current and former members of the Company’s Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The complaint in this case contains allegations similar to those in the Snee Derivative Litigation, the Presura Derivative Litigation, and the Securities Litigation, and it alleges that beginning in 2021, various of the defendants breached fiduciary duties, misappropriated information to conduct insider trading, and were unjustly enriched by making materially false and misleading statements or omissions regarding the Company’s recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels.
On September 19, 2024, the Delaware Court of Chancery issued an order consolidating and staying the Manfre Derivative Litigation, Presura Derivative Litigation, and Snee Derivative Litigation.
On November 26, 2024, the Company was named as a defendant in a putative class action filed in the SDNY Court captioned North Collier Fire Control and Rescue District Firefighters’ Retirement Plan v. Dentsply Sirona Inc., et al., No. 1:24-cv-09083 (the “North Collier Action”). On December 18, 2024, the Company was named as a defendant in a putative class action filed in the SDNY Court captioned Calvin v. Dentsply Sirona Inc., et al., No. 1:24-cv-09764 (the “Calvin Action”), and on December 19, 2024, the Company was named as a defendant in a putative class action filed in the SDNY Court captioned Key West Police & Fire Pension Fund v. Dentsply Sirona Inc., et al., No. 1:24-cv-09819 (the “Key West Action”). The complaints in these three cases allege that, for different alleged class periods over the period from May 6, 2021 through November 6, 2024, the Company and certain current and former officers violated U.S. securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the performance of the Company’s Byte aligners business, following the Company’s acquisition of Byte LLC in December 2020. On February 21, 2025, the SDNY Court entered an order consolidating the North Collier Action, the Calvin Action, and the Key West Action under the caption In re Dentsply Sirona, Inc. Securities Litigation, No. 24-cv-9083, and appointing HANSAINVEST Hanseatische Investment-Gesellschaft mit beschränkter Haftung and City of Miami General Employees’ & Sanitation Employees’ Retirement Trust as lead plaintiffs (“Lead Plaintiffs”) and Bernstein Litowitz Berger & Grossmann LLP as lead counsel for the consolidated case. The SDNY Court ordered the Lead Plaintiffs to file an amended complaint by April 7, 2025.
On March 21, 2023, Mr. Carlo Gobbetti filed a claim in the Milan Chamber of Arbitration against Dentsply Sirona Italia S.r.l. (“DSI”), Italy, a wholly owned subsidiary of the Company, seeking a total of €28 million for the alleged failure to pay a portion of the purchase price pursuant to a Share Purchase Agreement, dated October 8, 2012 (the “SPA”), in which Sirona Dental Systems, S.r.l., which at the time of execution of the SPA was a wholly-owned subsidiary of Sirona Dental Systems, Inc., acquired all of the shares of MHT S.p.A., an Italian corporation, from Mr. Gobbetti, and various other sellers. Sirona Dental Systems S.r.l. merged into Dentsply Italia S.r.l. in 2018 (the surviving entity is now Dentsply Sirona Italia S.r.l.). Under the SPA, a portion of the purchase price equal to €7 million was required to be deposited into an escrow account (the “Escrow Account”) and released to Mr. Gobbetti and the other sellers upon the satisfaction of certain conditions, including the delivery by July 2013 of a new prototype of an MHT S.p.A. camera which had to meet certain specifications. In connection with the closing of the share purchase transaction, the SPA was supplemented by a Facility Agreement, also dated October 8, 2012 (the “FA”), which specifically set out the mechanics of payment and release of the proceeds of the Escrow Account. The Austrian notary public, Mr. Gottfried Schachinger, acting as escrow agent, Mr. Gobbetti, and SIRONA Holdings GmbH, an affiliate of Sirona Dental Systems, Inc. which paid the €7 million into the Escrow Account, were parties to the FA. The FA is subject to Austrian law and to the jurisdiction of the Court of Salzburg in Austria.
Mr. Gobbetti claims that he is entitled to receive the €7 million outstanding balance of the purchase price under the SPA, plus €21 million for damages incurred as a consequence of the failure to make the payment. Mr. Gobbetti claims that he has a right to receive the full purchase price under the SPA even if the conditions set out in the SPA to deliver a prototype of the MHT S.p.A. camera by July 2013 were not met. On May 15, 2023, DSI filed its initial statement of defense denying that Mr. Gobbetti and the other sellers were entitled to receive the funds deposited in the Escrow Account and further disputing the allegations. Following the constitution of the arbitral tribunal, hearings were held on September 13, 2023 and January 19, 2024, to illustrate and discuss the positions of the parties. The parties also developed their arguments in several rounds of defensive briefs. The final submissions were completed on April 15, 2024 and the final hearing for discussion took place on May 8, 2024. On July 22, 2024, the arbitral tribunal rejected all of Mr. Gobbetti’s claims, ruling that the Company had met its contractual obligations under the SPA, particularly regarding the balance of the purchase price. The arbitral tribunal also dismissed Mr. Gobbetti’s claims in tort and those pertaining to the FA for lack of jurisdiction and lack of capacity for the Company to be sued. The arbitral tribunal observed that such claims should have been brought against SIRONA Holdings GmbH, which is a party to the FA but not to the SPA, before the Court of Salzburg in Austria based on the jurisdictional clause of the FA.
Mr. Gobbetti appealed the ruling of the arbitral tribunal on December 2, 2024 before the Court of Appeals of Milan, Italy (the “Court of Appeals”) arguing that the ruling is null and void. According to Mr. Gobbetti, the arbitral tribunal did not grant him appropriate defense rights under the Italian Civil Code and did not fully address the merits of his claims, despite acknowledging jurisdiction. Mr. Gobbetti asked the Court of Appeals to directly sentence DSI to pay the €7 million, plus damages of €21 million. DSI must submit its defense by March 20, 2025.
Except as noted above, no specific amounts of damages have been alleged in these lawsuits. The Company will continue to incur legal fees in connection with these pending cases, including expenses for the reimbursement of legal fees of present and former officers and directors under indemnification obligations. The expense of continuing to defend such litigation may be significant. The Company intends to defend these lawsuits vigorously, although the Company may elect to settle certain litigation matters, but there can be no assurance that the Company will be successful in any defense or that matters can be settled on terms favorable to the Company. If any of the lawsuits are decided adversely, the Company may be liable for significant damages directly or under its indemnification obligations, which could adversely affect the Company’s business, results of operations and cash flows. At this stage, the Company has accrued losses which are deemed probable, along with related insurance receivables, but the Company is unable to assess whether any incremental material loss or adverse effect is reasonably possible as a result of these lawsuits or estimate the range of any potential loss.
The Internal Revenue Service (“IRS”) is conducting an examination of the Company’s U.S. federal income tax returns for the tax years 2015 and 2016. The Company received a Notice of Proposed Adjustment in April 2023 and a Revenue Agent Report in January 2024 from the IRS examination team proposing an adjustment related to an internal reorganization completed in 2016 with respect to the integration of certain operations of Sirona Dental Systems, Inc. following its acquisition in 2016. Although the proposed adjustment does not result in any additional federal income tax liability for the internal reorganization, if sustained, the proposed adjustment would result in the Company owing additional federal income taxes on a distribution of $451 million related to a stock redemption that occurred after the internal reorganization was completed in 2016. The proposed adjustment, if sustained, would also result in a loss of foreign tax credits carried forward to later tax years. The Company believes that it accurately reported the federal income tax consequences of the internal restructuring and stock redemption in its tax returns and in April 2024, submitted an administrative protest with the IRS Independent Office of Appeals contesting the examination team’s proposed adjustments. The IRS examination team provided the Company with a rebuttal to the Company’s administrative protest during August 2024 and informed the Company that the dispute would be forwarded to the IRS Independent Office of Appeals.
The General Public Prosecutor’s Office Frankfurt am Main is investigating a series of intercompany loans implemented in 2016 and 2017 as part of the post-merger integration activities of DENTSPLY International Inc. and Sirona Dental Systems, Inc. The Company is cooperating with the investigation. The Company believes that the transactions at issue complied with all applicable German laws. No charges have been filed against the Company or any individuals.
The Company intends to vigorously defend its positions and pursue related appeals in the above-described pending matters and believes it is more likely than not that its positions will be sustained, although the Company may elect to settle certain matters. Unless otherwise disclosed herein, the Company has not accrued losses for these matters because the Company does not believe the risk of loss is probable and cannot estimate the range of any potential loss with any reasonable degree of accuracy.
In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company’s products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury, and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory, damages. Except as otherwise noted, the Company generally cannot predict what the eventual outcome of the above-described pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the eventual loss, fines or penalties related to each pending matter may be. Based upon the Company’s experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position, or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations, or liquidity.
While the Company maintains general, product, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary and directors’ and officers’ liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses.
Commitments
Purchase Commitments
The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At December 31, 2024, non-cancelable purchase commitments were as follows:
| (in millions) | |
|---|---|
| 2025 | $194 |
| 2026 | 69 |
| 2027 | 43 |
| 2028 | 40 |
| 2029 | — |
| Thereafter | — |
| Total | $346 |
The table above includes commitments under the Company’s agreement with a cloud services provider supporting the Company’s digital platform which requires minimum purchases totaling $85 million through 2028.
Off-Balance Sheet Arrangements
As of December 31, 2024, the Company had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on the Company’s consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources other than certain items disclosed in the sections above.
Indemnification
In the normal course of business to facilitate sales of the Company’s products and services, the Company indemnifies certain parties, including customers, vendors, lessors, services providers, and others, with respect to certain matters, including, but not limited to, services to be provided by or for the Company, and intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim.
It is not possible to make a reasonable estimate of the maximum potential amount of indemnification under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Additionally, the Company has a limited history of prior indemnification claims, and the payments made under such agreements have not had a material effect on the Company’s results of operations, cash flows or financial position. Except as noted in the “Contingencies” section herein, as of December 31, 2024, the Company did not have any material indemnification claims that were probable or reasonably possible. However, to the extent that valid indemnification claims arise in the future, future payments by the Company could be significant and could have a material adverse effect on the Company’s results of operations or cash flows in a particular period.
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS
FOR THE YEARS ENDED DECEMBER 31, 2024, 2023, and 2022
| Additions | ||||||
|---|---|---|---|---|---|---|
| Description | Balance atBeginningof Period | ChargedTo CostsAnd Expenses | Charged toOtherAccounts | Write-offsNet ofRecoveries | TranslationAdjustment | Balanceat Endof Period |
| (in millions) | ||||||
| Allowance for doubtful accounts: | ||||||
| For the Year Ended December 31, | ||||||
| 2022 | $13 | $7 | $(2) | $(3) | $(1) | $14 |
| 2023 | 14 | 6 | (1) | (3) | 1 | 17 |
| 2024 | 17 | 14 | (9) | (6) | (2) | 14 |
| Inventory valuation reserve: | ||||||
| For the Year Ended December 31, | ||||||
| 2022 | $86 | $20 | $— | $(17) | $(7) | $82 |
| 2023 | 82 | 39 | — | (18) | 4 | 107 |
| 2024 | 107 | 26 | — | (22) | (13) | 98 |
| Deferred tax asset valuation allowance: | ||||||
| For the Year Ended December 31, | ||||||
| 2022 (a) | $267 | $3 | $382 | $(1) | $(6) | $645 |
| 2023 | 645 | 279 | 4 | (70) | 5 | 863 |
| 2024 | 863 | 691 | — | (39) | (12) | 1,503 |
(a) The increase charged to other accounts represents an increase in deferred tax assets related to the re-establishment of Luxembourg net operating loss carryforwards for which a corresponding increase to the valuation allowance was also recorded, with no net impact to tax expense.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.